pole3.comHealthcareFounded: 2014Funding to Date: $167.22MM
Third Pole Therapeutics is a biotechnology company that is developing and commercializing novel, portable inhaled nitric oxide (iNO) delivery systems for the treatment of pulmonary hypertension and other cardio-pulmonary diseases. The company's proprietary technology, known as the iNOventâ„¢ platform, enables on-demand, targeted delivery of iNO to patients in a variety of settings, including hospitals, clinics, and homes. Third Pole Therapeutics aims to improve patient outcomes and quality of life by providing safe, effective, and accessible iNO therapy.
View Enterprise Value for Third Pole Therapeutics.